Aktieanalys

Egetis Q3 2023: No surprises - Redeye

Redeye Publicerad: 08 Nov 2023 08:43

Redeye notes that Egetis’ Q3 report presented SEK12.2m in revenues and SEK-98.8m in operating expenses, which was more or less in line with expectations, albeit with a slightly higher OPEX than anticipated (SEK89m), mainly indicating a quarter of high activity in preparation for the future Emcitate launch, regulatory filing and also reflecting the started ReTRIAC trial with Emcitate. After the quarter, Egetis secured significant financing through a private placement and debt financing– a significant catalyst we argue. We don’t expect to make any significant adjustments to our valuation and will soon return with a more extensive take.

Länk till analysen i sin helhet: https://www.redeye.se/research/956498/egetis-q3-2023-no-surprises?utm_source=finwire&utm_medium=RSS

Nyheter om Egetis Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!